[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/spikes/melanoma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Binimetinib\" }]"}]},{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/melanoma.ts","type":"changed","fields":[{"field":"tldr","before":"\"The MEK inhibitor partnered with encorafenib; blocking the next step in the same relay stops the tumour rerouting around the BRAF block.\"","after":"\"Binimetinib is the MEK inhibitor partnered with encorafenib; blocking the next step in the same relay stops the tumour rerouting around the BRAF block.\""}]},{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","commit":"3a655d800a","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: melanoma, head and neck, thyroid (deep records with structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/melanoma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"pathways"},{"field":"drugs"},{"field":"trials"}]}]